Known targets — ChEMBL curated mechanism
BRAFFLT1FLT3FLT4KDRKITPDGFRBRAF1RET
The experimentally established mechanism targets of Sorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 5/20 | 1.00 |
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.81 |
| ▸ | BRAF known ✓ | P15056 | 4/20 | 0.81 |
| ▸ | RET known ✓ | P07949 | 3/20 | 0.81 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.81 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.81 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.81 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.81 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | NTSR1 | P30989 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.81 |
| ▸ | ABL1 | P00519 | 2/20 | 0.81 |
| ▸ | HTR1A | P08908 | 2/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.81 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorafenib SCHEMBL162935 | 1.00 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL29919725 | 1.00 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL18496409 | 1.00 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL28204502 | 0.99 | KDR (0.98) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL3660939 | 0.99 | KDR (0.98) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL16051185 | 0.97 | KDR (0.94) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL3664023 | 0.97 | KDR (0.94) | KDRAURKBNTSR1MC4RPAX8 | |
| Cm-4307 SCHEMBL14673524 | 0.95 | KDR (0.90) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL19322 | 0.93 | KDR (0.87) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL18264082 | 0.93 | KDR (0.86) | KDRAURKBNTSR1MC4RPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10928405-B2 | Devices and methods for determining and/or isolating cells such as circulating cancer or fetal cells | ANALIZA, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3080341-B1 | METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20190178901-A1 | DEVICES AND METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| EP-2739143-B1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | FLYNN GARY A (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9833455-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | SPACEFILL ENTERPRISES LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2016-10-20 | — | — | US | disclosed |
| US-9221805-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | Spacefill Enterprises LLP (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150160246-A1 | DEVICES AND METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | KDR 308/4885RAF1 95/4885BRAF 49/4885 |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | KDR 308/4885RAF1 95/4885BRAF 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.